New Haven-based Achillion Pharmaceuticals, Inc. said Wednesday it received a $15 million milestone payment for research related to a drug trial for chronic hepatitis C.
The payment comes from Janssen Research & Development, LLC., part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
The funding is related to enrollment in a Janssen phase 2b global clinical drug trial for patients with a form of the hep C virus infection. The trial was initiated in November 2016. The treatment in the trial is a combination of drugs that includes the Achillion-discovered NS5A inhibitor, odalasvir.
Milind Deshpande, president and CEO of Achillion, said the company looks forward to clinical advancement of the research thanks to this new infusion of funding.
Achillion uses a discovery and development approach to pursuing best-in-class oral antiviral therapy for chronic hepatitis C. More information about the trial is available at www.clinicaltrials.gov using the identifier NCT02765490.
